NASDAQ:TWSTTwist Bioscience Stock Price, Forecast & News

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TWST stock has increased by 34.6% and is now trading at $37.95. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Twist Bioscience.

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Twist Bioscience.

Twist Bioscience Corp (NASDAQ:TWST) announced its earnings results on Thursday, May, 7th. The company reported ($0.85) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.75) by $0.10. The firm earned $19.30 million during the quarter, compared to the consensus estimate of $17.18 million. Twist Bioscience had a negative return on equity of 71.31% and a negative net margin of 222.66%. Twist Bioscience's revenue for the quarter was up 41.9% compared to the same quarter last year. During the same period last year, the company earned ($0.93) earnings per share. View Twist Bioscience's earnings history.

2 brokerages have issued twelve-month price objectives for Twist Bioscience's shares. Their forecasts range from $42.00 to $42.00. On average, they expect Twist Bioscience's stock price to reach $42.00 in the next year. This suggests a possible upside of 10.7% from the stock's current price. View analysts' price targets for Twist Bioscience.

Media stories about TWST stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Twist Bioscience earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutTwist Bioscience.

Twist Bioscience saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 4,400,000 shares, an increase of 5.0% from the April 15th total of 4,190,000 shares. Based on an average trading volume of 611,600 shares, the days-to-cover ratio is currently 7.2 days. Approximately 16.5% of the company's shares are short sold. View Twist Bioscience's Current Options Chain.

Some companies that are related to Twist Bioscience include Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Ablynx (ABLYF), bluebird bio (BLUE), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Novavax (NVAX), Alector (ALEC), Fate Therapeutics (FATE) and Bill.com (RVMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include Canopy Growth (CGC), Gilead Sciences (GILD), Square (SQ), AbbVie (ABBV), Aurora Cannabis (ACB), Amarin (AMRN), Arcturus Therapeutics (ARCT), Alibaba Group (BABA), Inovio Pharmaceuticals (INO) and Iovance Biotherapeutics (IOVA).

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (7.62%), BlackRock Inc. (6.85%), Wellington Management Group LLP (3.75%), Casdin Capital LLC (2.82%), State Street Corp (2.71%) and Bank of New York Mellon Corp (2.60%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View institutional ownership trends for Twist Bioscience.

TWST stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Squarepoint Ops LLC, Federated Hermes Inc., Wells Fargo & Company MN, Morgan Stanley, Deutsche Bank AG, UBS Group AG, and Windsor Creek Advisors LLC. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, Emily M Leproust, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, and William Banyai. View insider buying and selling activity for Twist Bioscience.

TWST stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Bank of New York Mellon Corp, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Casdin Capital LLC, William Blair Investment Management LLC, and Redmile Group LLC. View insider buying and selling activity for Twist Bioscience.

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TWST stock can currently be purchased for approximately $37.95.

Twist Bioscience has a market capitalization of $1.56 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe.

The official website for Twist Bioscience is www.twistbioscience.com.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]